LGBCL: phase 2 study of intensified rituximab induction and maintenance
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
- In patients with newly diagnosed or rituximab-naive low-grade B-cell lymphoma (LGBCL), intensified rituximab (Rituxan) induction and maintenance delivered tolerable, impressive efficacy
Why this matters
- Risk scoring systems such as Sokal and European Treatment and Outcome Study (EUTOS) currently incorporate peripheral blood (PB) parameters.
- Phase 2 study to investigate the safety and efficacy of rituximab (Rituxan) as 8 weekly doses of induction and 2 y maintenance therapy in 36 patients with newly diagnosed or rituximab-naive LGBCL.
- Funding: Grant-in-Aid for Cli...